Premium
Dose–response relationship between statin therapy and glycaemia in community‐based patients with type 2 diabetes: the F remantle D iabetes S tudy
Author(s) -
Davis T. M. E.,
Badshah I.,
Chubb S. A. P.,
Davis W. A.
Publication year - 2016
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12710
Subject(s) - statin , medicine , type 2 diabetes , diabetes mellitus , concomitant , intensity (physics) , glycated hemoglobin , endocrinology , gastroenterology , physics , quantum mechanics
Although statins may increase glycaemia in type 2 diabetes, available data are from single‐dose intervention trials or studies with no adjustment for concomitant changes in blood glucose‐lowering therapy. To provide real‐life data covering common statin types and doses, glycated haemoglobin ( HbA1c ) data from patients in the F remantle D iabetes S tudy phases I ( FDS1 ) and II ( FDS2 ) and data on stable diabetes treatment before and after statin initiation were analysed. Intensity of statin therapy was categorized as low, moderate or high based on within‐group dose regimens with similar serum LDL cholesterol‐lowering effects. In pooled analyses of 335 eligible patients in FDS1 and FDS2 , there was no change in HbA1c in the low‐intensity group (0.04% or 0.4 mmol/mol; n = 159; p = .40), but a mean 0.22% (2.4 mmol/mol) increase in the moderate‐intensity group (n = 185; p = .022) and a larger mean increase of 1.05% (11.5 mmol/mol) increase in the high‐intensity group (n = 11; p = .023). These real‐life data suggest a dose–response relationship between statin treatment intensity and glycaemia that has potential clinical implications.